Far Infrared Irradiation for Managing and Treating Multiple Sclerosis (MS)
Primary Purpose
Multiple Sclerosis
Status
Unknown status
Phase
Phase 1
Locations
Canada
Study Type
Interventional
Intervention
Far Infrared Radiation (5μm to 20μm wavelength)
Sponsored by

About this trial
This is an interventional treatment trial for Multiple Sclerosis focused on measuring MS (Multiple Sclerosis), Multiple Sclerosis, Acute Fulminating, Sclerosis, Disseminated
Eligibility Criteria
Inclusion Criteria:
- Patients with MS
Exclusion Criteria:
- None
Sites / Locations
- The Centre for Incurable Diseases
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
1
Arm Description
Radiation
Outcomes
Primary Outcome Measures
Treatment of MS
Secondary Outcome Measures
Rehabilitation of MS Patients
Full Information
NCT ID
NCT00674934
First Posted
May 6, 2008
Last Updated
January 2, 2009
Sponsor
GAAD Medical Research Institute Inc.
1. Study Identification
Unique Protocol Identification Number
NCT00674934
Brief Title
Far Infrared Irradiation for Managing and Treating Multiple Sclerosis (MS)
Official Title
Phase 1 Study to Determine the Efficacy of Using Far Infrared Radiation for Multiple Sclerosis.
Study Type
Interventional
2. Study Status
Record Verification Date
January 2009
Overall Recruitment Status
Unknown status
Study Start Date
May 2008 (undefined)
Primary Completion Date
May 2010 (Anticipated)
Study Completion Date
June 2010 (Anticipated)
3. Sponsor/Collaborators
Name of the Sponsor
GAAD Medical Research Institute Inc.
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Multiple sclerosis (abbreviated MS) is an autoimmune condition in which the immune system attacks the central nervous system (CNS), leading to demyelination. This study will investigate the use of far infrared radiation for MS control, management and treatment.
Detailed Description
MS a demyelinating disease, is any disease of the nervous system in which the myelin sheath of neurons is damaged. This impairs the conduction of signals in the affected nerves, causing impairment in sensation, movement, cognition, or other functions depending on which nerves are involved.
MS affects the areas of the brain and spinal cord known as the white matter. White matter cells carry signals between the grey matter areas, where the processing is done, and the rest of the body. More specifically, MS destroys oligodendrocytes which are the cells responsible for creating and maintaining a fatty layer, known as the myelin sheath, which helps the neurons carry electrical signals.
Observations from our research studies indicate that, far infrared rays provide energy to the body, improve the autonomic functions of the nervous system, restore the functions of the endocrine system, strengthen the immune system, improve blood circulation and increase the level of oxygen in the cells and promote the regeneration of muscle cells, nerves and brain cells.
It is hereby postulated that irradiation using far infrared, with wavelength between 5 to 20 microns, of the central nervous system, the endocrine system and the whole body could prevent, control, manage or possibly lead to complete rehabilitation of people who have MS.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Multiple Sclerosis
Keywords
MS (Multiple Sclerosis), Multiple Sclerosis, Acute Fulminating, Sclerosis, Disseminated
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
5 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
1
Arm Type
Experimental
Arm Description
Radiation
Intervention Type
Radiation
Intervention Name(s)
Far Infrared Radiation (5μm to 20μm wavelength)
Other Intervention Name(s)
Far Infrared Radiation
Intervention Description
Far Infrared Radiation (5μm to 20μm wavelength). Far Infrared radiation for 30 to 40 minutes per treatment session.
Primary Outcome Measure Information:
Title
Treatment of MS
Time Frame
2 years
Secondary Outcome Measure Information:
Title
Rehabilitation of MS Patients
Time Frame
2 Years
10. Eligibility
Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients with MS
Exclusion Criteria:
None
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ken Nedd, M.D.
Organizational Affiliation
GAAD Medical Research Institute Inc.
Official's Role
Principal Investigator
Facility Information:
Facility Name
The Centre for Incurable Diseases
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M4V 1L5
Country
Canada
12. IPD Sharing Statement
Learn more about this trial
Far Infrared Irradiation for Managing and Treating Multiple Sclerosis (MS)
We'll reach out to this number within 24 hrs